Novo Nordisk has released the findings of its REDEFINE 2 trial, which compared the new weight loss drug, CagriSema, in adults with type 2 diabetes and overweight or obesity. CagriSema consists of two drugs, cagrilintide and semaglutide, aimed at suppressing hunger and weight loss.
The 68-week trial involved 1,206 people. It showed people who took CagriSema lost more weight than people who took a placebo (dummy treatment). On average, people lost 15.7% of their body weight on CagriSema, compared to only 3.1% on the placebo. In addition, nearly 90% of people who took CagriSema lost over 5% of their weight.
The therapy was well tolerated in general, with most of the most common side effects being mild-to-moderate gastrointestinal distress, which was reversible.
The study forms part of a wider research program referred to as the REDEFINE programme, and it involves various trials of CagriSema for obesity and diabetes treatment. Novo Nordisk plans to file the drug for regulatory approval in 2026.
